Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna Tumor Chemoresistance Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0758

    Tumor Chemoresistance Assays

    Customize your policy alerts

    Sign up for Aetna Policy 0758 alerts

    Get alerted when Policy 0758 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance on tumor chemoresistance and chemosensitivity assays used to guide chemotherapy selection; applies to providers submitting claims for these laboratory assays.

    Policy Summary
    PayerAetna
    PolicyTumor Chemoresistance Assays
    Policy CodePolicy 0758
    Change TypeNo material changes
    Effective DateJun 20, 2008
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not use in‑vitro chemoresistance assays to select chemotherapy regimens; these assays are considered experimental and investigational and may be denied.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2008-06-20policy effective date
    2023-10-11last review
    2024-08-22next review
    5 RCTsRCTs in ASCO review
    ~82bibliographic refs

    Coverage Determination and Criteria

    Coverage determination

    Covered when ALL of the following are met:

    Experimental and Investigational Determination: Tumor chemoresistance assays are considered experimental and investigational by Aetna because there is insufficient evidence that these assays influence management decisions such that clinical outcomes are improved.

    Policy-level coverage determination

    Aetna considers tumor chemoresistance assays experimental and investigational because there is insufficient evidence that these assays influence clinical management decisions in a way that improves patient outcomes. Claims for services that are billed as tumor chemoresistance or related assay testing may be denied on this basis.

    The American Society of Clinical Oncology (ASCO) clinical practice guideline (Partridge et al., 2014) states that in‑vitro chemoresistance assays should not be used to select treatment. The guideline reflects the absence of adequate evidence showing that tailoring chemotherapy based on these assays improves outcomes.

    This Clinical Policy Bulletin is intended to assist in administering plan benefits and does not constitute a contract or medical advice. It provides a partial, general description of plan or program benefits; treating providers remain responsible for medical advice and treatment decisions for members.

    ASCO does not support the use of in‑vitro chemoresistance assays to direct selection of chemotherapy regimens. In addition, the U.S. Food and Drug Administration has cited examples of insufficiently validated laboratory‑developed tests (LDTs) used to predict chemotherapy response that may have caused patient harm when used to guide treatment decisions.

    Billing Codes

    CPT codes related to the policyCPT
    87230Toxin or antitoxin assay, tissue culture (e.g., Clostridium difficile toxin)
    88104Cytopathology, fluids, washings or brushing, except cervical or vaginal; smears with interpretation
    88305Level IV surgical pathology, gross and microscopic examination
    88313Special stain including intrepretation and report; Group II, all other (e.g., iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry
    88358Morphometric analysis; tumor (e.g., DNA ploidy)
    89050Cell count, miscellaneous body fluids (e.g., cerebrospinal fluid, joint fluid), except blood
    Other CPT codes related to the policyCPT
    88230Tissue culture for non-neoplastic disorders; lymphocyte
    88233skin or other solid tissue biopsy
    88235amniotic fluid or chorionic villus cells
    88237Tissue culture for neoplastic disorders; bone marrow, blood cells
    88239solid tumor
    HCPCS range referencedHCPCS
    J9000-J9999Chemotherapy drugs
    ICD-10 codes referencedICD-10
    C00.0-D49.9Neoplasms
    Z51.11-Z51.12Encounter for antineoplastic chemotherapy and immunotherapy

    Provider Actions, Prior Authorization, and Denial Risk

    Prior Authorization

    Prior Authorization / Denial Risk

    Prior authorization: No specific prior authorization process is specified in the extracted policy text. However, providers should be aware that tumor chemoresistance assays are considered experimental and investigational by Aetna and that claims for these assays may be denied; appropriate justification and documentation should be submitted if providers choose to request coverage determination. Codes associated with these assays (see coding list) may be subject to review and denial when billed for neoplasm-related indications.

    • No specific prior authorization requirement stated in extracted material; submit clinical justification if requesting coverage.
    • Anticipate denial risk for tests billed with neoplasm (C00.0-D49.9) or chemotherapy encounter (Z51.11-Z51.12) diagnoses.
    • Affected codes (examples): CPT 87230, 88104, 88305, +88313, 88358, 89050; related CPTs 88230, 88233, 88235, 88237, 88239; HCPCS range J9000-J9999 for chemotherapy drugs.
    Documentation Required

    Background and Scope

    Chemoresistance and chemosensitivity assays are in‑vitro laboratory tests performed on tumor tissue or cells to evaluate whether specific chemotherapeutic agents are likely to be ineffective (chemoresistance) or effective (chemosensitivity) for an individual patient. Typical methods isolate tumor cells, expose them to single agents or drug panels, and assess cell survival, growth, or metabolic activity to infer drug response. Variants include assays claiming very high negative predictive value (for example, extreme drug resistance (EDR) assays with reported NPV >99%) and other laboratory‑developed approaches; however, available evidence does not demonstrate that use of these assays to select therapy leads to improved clinical outcomes.

    Key Definitions

    inv-23: Definition — Chemoresistance assay
    DefinitionAn in-vitro laboratory test intended to identify chemotherapeutic agents that are ineffective (resistant) against a patient's tumor.
    Typical processIsolation of tumor cells, incubation with anti-cancer drugs, assessment of cell growth/survival, interpretation of results.
    Common examplesExtreme Drug Resistance (EDR) assay; Duke University Chemotherapy Assessment Test; used alone or with molecular profiling (e.g., BioSpeciFx, Target Now).
    inv-24: Definition — Chemosensitivity assay
    DefinitionAn in-vitro laboratory test performed to evaluate tumor growth response to a known chemotherapeutic drug or panel of drugs to identify potentially effective agents.
    PurposeTo assess whether tumor growth is inhibited by specific drugs or panels to help guide selection of potentially effective chemotherapy.

    Biomarkers and Molecular Findings

    inv-29: Biomarkers listed — MGMT, GSTP1, mutant p53, TFAP2E, DKK4, miR-125b
    MGMTO(6)-methylguanine-DNA methyltransferase (MGMT) — overexpression associated with in-vitro resistance in malignant gliomas (reported 67% overexpression).
    GSTP1Glutathione S-transferase pi (GSTP1) — overexpression associated with in-vitro resistance in malignant gliomas (reported 49% overexpression).
    mutant p53Mutant p53 — detected in a substantial percentage of brain tumors and associated with drug resistance (reported 41% overexpression).
    TFAP2ETFAP2E — listed among biomarkers of interest in chemoresistance research within the policy background.
    DKK4DKK4 — listed among biomarkers of interest in chemoresistance research within the policy background.
    miR-125bmiR-125b — included in the list of specific biomarkers discussed in the policy background and literature summaries.

    Therapeutic Strategies and Preclinical Evidence

    Preclinical findingModel / contextImplication for overcoming chemoresistanceCoverage status
    Axl inhibition increases sensitivity to doxorubicinPreclinical breast cancer models: gene expression and phospho-RTK comparison between MCF-7 (sensitive) and MCF-7/ADR (doxorubicin-resistant); Axl analyzed across 57 breast cancer cell lines; in vitro Axl inhibitor R428 combined with doxorubicinAxl silencing or pharmacologic inhibition (R428) enhanced cell death with doxorubicin and reduced invasive/metastatic potential, suggesting the Gas6/Axl axis as a therapeutic target to overcome multi-drug resistanceExperimental
    STAT5b targeting sensitizes pancreatic cancer cells to gemcitabinePreclinical pancreatic ductal adenocarcinoma cell line studies (multiple PDAC lines including PANC-1, AsPC-1, BxPC3); STAT5b expression manipulated by shRNA or overexpressionSTAT5b knockdown reduced chemoresistance to gemcitabine and increased apoptosis (PARP and cleaved caspase-3 activation); overexpression increased resistance, indicating STAT5b as a potential target to sensitize PDAC to gemcitabineExperimental

    Policy Dates and Revision History

    2023-10-11last_reviewLatest

    Policy last reviewed on 2023-10-11.

    2008-06-20effective_date

    Policy effective since 2008-06-20.

    2024-08-22next_review

    Next scheduled review on 2024-08-22.

    Policy Summary
    PayerAetna
    PolicyTumor Chemoresistance Assays
    Policy CodePolicy 0758
    Change TypeNo material changes
    Effective DateJun 20, 2008
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not use in‑vitro chemoresistance assays to select chemotherapy regimens; these assays are considered experimental and investigational and may be denied.
    SourceLink
    On This Page
    Coverage Determination and CriteriaBilling CodesProvider Actions, Prior Authorization, and Denial RiskBackground and ScopeKey DefinitionsBiomarkers and Molecular FindingsTherapeutic Strategies and Preclinical EvidencePolicy Dates and Revision History

    ASCO Guideline and LDT Safety Note

    ASCO guidance: The American Society of Clinical Oncology (ASCO) states that in‑vitro chemoresistance assays should not be used to select treatment. This guideline position supports the determination that such assays are not medically necessary for directing chemotherapy regimens.

    • Provider action: Do not use in‑vitro chemoresistance assay results as the sole basis for selecting chemotherapy regimens; document rationale for any deviation.
    • LDT concern: FDA cited the Duke Chemotherapy Assessment Test as an insufficiently validated LDT that may have caused harm; insufficient validation is a rationale for denying coverage.
    Denial Risk

    Provider Actions

    Provider actions: Because Aetna designates tumor chemoresistance assays as experimental/investigational due to insufficient evidence of improved clinical outcomes, providers should expect coverage denial unless compelling, documented justification is provided through the plan's coverage review process. Clinical Policy Bulletins are administrative guidance and do not guarantee coverage.

    • When ordering or billing for these assays, include detailed clinical rationale and supporting evidence if requesting an exception or preauthorization review.
    • Be prepared for medical record review and potential claim denial for neoplasm-related indications.
    • Use the related policy (CPB 0245) and submitted evidence to support any coverage requests.
    Relationship to chemoresistance assaysShares principles with chemoresistance assays but focuses on identifying potentially effective (sensitive) agents rather than deselecting ineffective ones.
    inv-25: Definition — Extreme Drug Resistance (EDR) assay
    DefinitionAn assay designed to provide very high negative predictive value (>99%) to deselect ineffective chemotherapies by measuring thymidine uptake after drug exposure.
    MethodTumor cells from fresh biopsy are labeled with tritiated thymidine; uptake after exposure to clinically relevant drug concentrations is measured to identify extreme resistance.
    Interpretation thresholdExtreme resistance identified when thymidine incorporation is inhibited by less than 1 standard deviation of the median cell inhibition measured for several hundred reference tumor samples.
    inv-26: Definition — Non-coding RNAs (ncRNAs) including miRNAs, snoRNAs, lncRNAs
    DefinitionTranscripts without protein-coding potential including microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).
    Role in chemoresistanceDeregulated ncRNAs (miRNAs, lncRNAs, snoRNAs) are implicated as regulators of drug resistance and potential prognostic biomarkers or therapeutic targets.
    Clinical implicationInvestigators suggest tumor-specific ncRNAs may help predict response and guide individualized chemotherapy, but further translational research is needed.
    inv-27: Definition — Laboratory Developed Test (LDT)
    DefinitionA diagnostic test developed and used within a single laboratory (laboratory developed test, LDT).
    Regulatory noteFDA has cited insufficiently validated LDTs (example: Duke University Chemotherapy Assessment Test) as having potentially caused patient harm when used to guide chemotherapy.
    Coverage implicationUse of insufficiently validated LDTs to select chemotherapy may lead to denial of clinical utility or adverse regulatory attention.
    inv-28: Policy History / Definitions link indicator
    Policy history accessPolicy History (link indicated) — Last Review: 10/11/2023; Next Review: 08/22/2024; Effective: 06/20/2008.
    Definitions linkDefinitions (link indicated) — opens policy definitions page for related terms.
    Review notesReview history and detailed change log available via linked Review History in the policy bulletin.
    inv-30: Biomarkers listed — miRNAs, lncRNAs, ncRNAs
    miRNAsMicroRNAs (miRNAs) — implicated in drug resistance across multiple cancers and discussed as potential predictive biomarkers and therapeutic targets.
    lncRNAsLong non-coding RNAs (lncRNAs) — deregulated lncRNAs play roles in chemoresistance and may serve as prognostic biomarkers or targets.
    ncRNAs (general)Non-coding RNAs (ncRNAs) — includes miRNAs, snoRNAs, lncRNAs and circRNAs; implicated in mechanisms of chemoresistance in hepatocellular and colorectal cancers.
    inv-31: Biomarker — CD44s / CD44v6
    CD44sCD44 standard (CD44s) — high expression associated with chemoresistance in ovarian cancer (OR 5.94) and shorter disease-free survival in a meta-analysis (24 studies, 2,267 patients).
    CD44v6CD44 variant 6 (CD44v6) — expression was not correlated with FIGO stage, tumor differentiation, nodal metastasis, or overall survival in analyzed studies.
    Clinical interpretationHigh CD44s expression potentially indicates poor prognosis and is associated with chemotherapy resistance, but further confirmation is needed before clinical application.